

Cycle view of the study programme

Bl Or Th Pr Au Cr

Information

Professor Ph. HUBERT
Analytical Chemistry Laboratory
Building B36 - CHU - 4000 Liège
Phone : 04/366.43.16 - Fax : 04/366.43.17
e-mail address : Ph.Hubert@ulg.ac.be

Collegiality

For the ULg : Vincent BIERLAIRE, Bruno BOULANGER, Raphaël DENOZ, Laurence DENIS, Brigitte EVRARD, Marianne FILLET, Michel FREDERICH, Philippe HUBERT, Roland MARINI, Dominique MARTIN, Bernard PIROTTE, Régis RADERMECKER, Jean-Michel VANDERHOFSTADT, Eric ZIEMONS.

For the ULB : Karim AMIGHI, Sonja BEKEN, Daniel BRASSEUR, Jean-Antoine DE MUYLDER, Patrick DI STEFANO, Pierre DUEZ, François DUFRASNES, Véronique FONTAINE, Ghanem GHANEM, Jean-Michel KAUFFMAN, A. LENAERS, Pierre VAN ANTWERPEN, Francis VANDERBIST, David VERMIJLEN.

For the UCL : Catherine DRUEZ, Laure ELENS, Xavier MARCELIS, François-Xavier MATHY, Jacques POUPAERT, Thierry PRONCE, Joëlle QUETIN-LECLERCQ, Nevin SERBEST, Rita VAN BEVER.

Study programme

Compulsory courses (B1 : 60Cr)

Code	Course Title	Bl	Or	Th	Pr	Au	Cr
PHIN2004-1	<i>Active substances</i>	B1	Q1				6
	- <i>Substances issues de recherches pharmacochimiques, part a</i> - Bernard PIROTTE		10	-	-		
	- <i>Substances issues de recherches pharmacochimiques, part b</i> - Françoise DUFRASNE		5	-	-		
	- <i>Substances issues des biotechnologies</i> - David VERMIJLEN		15	-	-		
	- <i>Substances d'origine naturelle, part a</i> - Joëlle QUETINLECLERCQ		5	-	-		
	- <i>Substances d'origine naturelle, part b</i> - Pierre DUEZ		5	-	-		
	- <i>Produits radiopharmaceutiques</i> - Ghanem GHANEM		10	-	-		
PHIN2008-2	<i>Clinical viewpoints</i>	B1	Q1				6
	- <i>Métabolisme des médicaments et paramètres pharmacocinétiques</i> - FrançoisXavier MATHY		20	-	-		
	- <i>Aspects théoriques et pratiques des études cliniques (y compris les méthodes statistiques appliquées aux études cliniques)</i> - Régis RADERMECKER		15	-	-		
	- <i>Information et pharmacovigilance</i> - Raphaël DENOZ		10	-	-		
PHIN2013-2	<i>Quality assurance and pharmaceutical management</i>	B1					7
	- <i>Principles of pharmaceutical management</i> - JeanMichel VAN DER HOFSTADT		10	-	-		
	- <i>Quality assurance, part a : basic concepts and quality assurance organisation</i> - Thierry PRONCE		20	-	-		
	- <i>Quality assurance, part b : Analytical technology of procedures and risk analysis</i> - Xavier MARCELIS		7,5	-	-		
	- <i>English applied to the pharmaceutical industry</i> - Jacques POUPAERT, Nevin SERBEST		20	-	-		
- <i>Pharmaceutical marketing</i> - Vincent BIERLAIRE		7,5	-	-			
PHIN2033-1	<i>Industrial pharmaceutical technology</i>	B1					8
	- <i>Industrial pharmaceutical microbiology</i> - Véronique FONTAINE		15	-	-		
	- <i>Preformulation and selection of galenical forms</i> - Karim AMIGHI		15	-	-		
	- <i>Industrial production of galenical forms</i> - Brigitte EVRARD		15	-	-		
	- <i>Industrial production of biomolecules</i> - Rita VAN BEVER		15	-	-		
	- <i>Industrial aspects of technological development including packaging</i> - Laurence DENIS		10	-	-		
PHIN2023-1	<i>Drug analysis</i>	B1					7
	- <i>Analytical methods and pharmaceutical and biopharmaceutical control, part a</i> - JeanMichel KAUFFMAN, Pierre VAN ANTWERPEN		10	-	-		
	- <i>Analytical methods and pharmaceutical and biopharmaceutical control, part b</i> - Marianne FILLET		10	-	-		

	- <i>Methods in pharmaceutical and biopharmaceutical analysis, part a : Validation and qualification of equipment</i> - Philippe HUBERT, Roland MARINI DJANG'EING'A	15	-	-	
	- <i>Methods in pharmaceutical and biopharmaceutical analysis, part b : Process analytical technology</i> - Philippe HUBERT, Eric ZIEMONS	5	-	-	
	- <i>Statistical methods applied to the pharmaceutical industry</i> - Laure ELENS	15	-	-	
	- <i>Experimental planning and "quality by design"</i> - Bruno BOULANGER	10	-	-	
PHIN2029-2	<i>Regulation and the medical-social environment</i>	B1			8
	- <i>Economic aspects of drug development</i> - Dominique MARTIN	10	-	-	
	- <i>Legislation and procedures applied to pharmaceutical industry, part a : legislation</i> - Catherine DRUEZ	10	5	-	
	- <i>Legislation and procedures applied to pharmaceutical industry, part b : patents and protection</i> - Patrick DI STEFANO	5	-	-	
	- <i>Macroeconomic environment and pharmaco-economics</i> - Pierre DUEZ	10	-	-	
	- <i>CTD File (Common Technical Document)</i> - JeanAntoine DE MUYLDER	15	-	-	
	- <i>Regulations of preclinical and clinical studies, part a : pharmaceutical toxicological files</i> - Sonia BEKEN	15	-	-	
	- <i>Regulations of preclinical and clinical studies, part b : clinical studies</i> - Anne LENAERS	5	-	-	
	- <i>Regulations of preclinical and clinical studies, part c : pediatric studies</i> - Daniel BRASSEUR	2,5	-	-	
	- <i>Specific regulatory issues, part a : medicine and herbal dietary supplement</i> - Michel FREDERICH	5	-	-	
	- <i>Specific regulatory issues, part b : Preformulation and galenical development documentation</i> - Francis VANDERBIST	5	-	-	
PHIN2032-1	<i>Visits and seminars organised in the pharmaceutical industry</i> - Françoise DUFRASNE, Marianne FILLET, Rita VAN BEVER - [77,5h Vis.]	B1	-	-	[+] 3
MTFE2000-1	<i>Final work</i> - Brigitte EVRARD, Philippe HUBERT	B1	-	-	15